EPHX2 and atherosclerosis: sEH polymorphisms are associated with an increased risk in atherosclerosis in a number of clinical studies [17]–[19], and treatment of apolipoprotein E knockout mice with synthesized sEH inhibitors for 8 weeks reduced atherosclerosis in these animals [20].